Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs

Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs

The study aimed to present our experience in treating recurrent HCV genotype 4 infection post living donor liver transplantation (LDLT) since introduction of the second generation direct acting antiviral drugs (DAAs) in Egypt.

This was a cohort study conducted in patients who had undergone LDLT for HCV related disease from 2014 to 2016 at in Ain Shams Center for Organ Transplantation (ASCOT) .The hypothesis early initiation of DAAs( after 12 weeks of the operation ) is effective and safe strategy in transplant recipients following LDLT. Patients who take the sofosbuvir and ribavirin after 6 months after transplantation were compared with those who take early treatment after 3 months of transplantation with sofosbuvir and daclatsvir+/- ribavirin..Patients were on regular follow up visits monthly to assess the clinical condition, any side effects, laboratory tests including complete blood picture, liver functions , renal functions and trough level of immunosuppressant drugs.

Inclusion Criteria:

• All transplanted patients for HCV related disease in the period from 2014 to 2016

Exclusion Criteria:

• Patients transplanted for other causes rather than HCv
• Patients with HBV and HCV co infection